Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aimmune Therap (AIMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,183,413
  • Shares Outstanding, K 50,530
  • Annual Sales, $ 0 K
  • Annual Income, $ -80,820 K
  • 36-Month Beta -1.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.95

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.90 +23.92%
on 08/21/17
23.95 -2.21%
on 09/13/17
+4.35 (+22.81%)
since 08/18/17
3-Month
18.25 +28.33%
on 08/09/17
23.95 -2.21%
on 09/13/17
+4.86 (+26.19%)
since 06/20/17
52-Week
14.11 +65.98%
on 09/29/16
27.31 -14.24%
on 11/14/16
+7.61 (+48.13%)
since 09/20/16

Most Recent Stories

More News
Arcus Biosciences Appoints Kate Falberg to Its Board of Directors

Arcus Biosciences, a biotechnology company focused on the discovery and development of innovative cancer immunotherapies, today announced the appointment of Kathryn ("Kate") Falberg to its...

AIMT : 23.42 (+0.69%)
URGN : 30.06 (-5.83%)
TTD : 59.81 (-3.09%)
AXON : 26.20 (+7.95%)
AMGN : 188.17 (+0.99%)
Aimmune Therapeutics to Participate in Three Investor Conferences in September

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management...

AIMT : 23.42 (+0.69%)
AIMSI Technologies Fair Fund Distribution Agent Announces Notice of Distribution Plan

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

AIMT : 23.42 (+0.69%)
AIMSI Technologies Fair Fund Distribution Agent Announces Notice of Distribution Plan

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

AIMT : 23.42 (+0.69%)
AIMSI Technologies Fair Fund Distribution Agent Announces Notice of Distribution Plan

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

AIMT : 23.42 (+0.69%)
Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company...

AIMT : 23.42 (+0.69%)
AVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8%

AVEO Pharmaceuticals, Inc. (AVEO) shares rose around 15% in the last trading session.

AVEO : 3.77 (-1.82%)
AIMT : 23.42 (+0.69%)
Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the European Phase 3 ARTEMIS (ARC010) clinical trial of AR101 for treatment of peanut allergy....

AIMT : 23.42 (+0.69%)
Aimmune Therapeutics (AIMT) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Aimmune Therapeutics Inc (AIMT).

AIMT : 23.42 (+0.69%)
Dynavax Technologies (DVAX) Catches Eye: Stock Gains 6.6%

Dynavax Technologies Corporation (DVAX) shares rose almost 7% in the last trading session.

AIMT : 23.42 (+0.69%)
DVAX : 21.05 (+0.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and...

See More

Support & Resistance

2nd Resistance Point 23.91
1st Resistance Point 23.66
Last Price 23.42
1st Support Level 23.09
2nd Support Level 22.77

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.